Sponsored by
Topics
Topics
Accounting & Tax
Corporate Finance
Human Capital
Risk & Compliance
Strategy
Technology
Featured
Risk & Compliance
Do You Spend Enough Time Assessing Strategic Risks?
Devote more time to strategic risk management and you won’t be caught completely unprepared.
By
Perry D. Wiggins, C.P.A.
| January 26, 2022
Read More
Resources
Sign Up
Menu
Topics
Accounting & Tax
Corporate Finance
Human Capital
Risk & Compliance
Strategy
Technology
Explore
Search
Sign Up
Sponsored by
Johnson & Johnson
Mergers & Acquisitions
Johnson & Johnson Borrows $7.5B to Fund Its Purchase Of Momenta
S&P Global Ratings said that the company’s adjusted debt to a measure of earnings is at a 15-year high.
By
Vincent Ryan
| August 21, 2020
Read More
M&A
Johnson & Johnson to Buy Momenta for $6.5B
The deal will give J&J control of nipocalimab, an experimental therapy Momenta is developing to treat autoimmune diseases.
By
Lauren Muskett
| August 19, 2020
Read More
Risk & Compliance
J&J Speeds Up Timeline for Coronavirus Vaccine
After lagging behind other companies, J&J now expects to begin a late-stage study of its vaccine candidate in September.
By
Matthew Heller
| July 16, 2020
Read More
Risk & Compliance
Johnson & Johnson to Start COVID-19 Vaccine Trials in July
The healthcare giant moved up the coronavirus human clinical trials timeline by about two months.
By
Lauren Muskett
| June 11, 2020
Read More
Risk & Compliance
Moderna Gets $483M to Fund Corona Vaccine
The grant from the U.S. government will boost Moderna's efforts to develop what is “among the most advanced coronavirus vaccine candidates.”
By
Matthew Heller
| April 17, 2020
Read More
Risk & Compliance
J&J Found Liable for Helping Cause Opioid Crisis
In a landmark ruling, an Oklahoma judge said the firm's opioid sales practices were false and misleading, endangering the safety of Oklahomans.
By
Matthew Heller
| August 27, 2019
Read More
Technology
J&J Buys Auris for $3B in Surgical Robotics Play
The deal is J&J's biggest move into surgical robotics, which "has been a gap for its medical device business."
By
Matthew Heller
| February 13, 2019
Read More
Financial Performance
J&J Gets Boost From Strong Cancer Drug Sales
The company's Q3 earnings beat estimates but "it remains too early to call for a broad recovery" in the medical-device and consumer businesses.
By
Matthew Heller
| October 16, 2018
Read More
Tax
Will New Tax Law Uproot Overseas Financial Structures?
The TCJA may force some U.S. companies to reconsider their strategy of shifting profits to affiliates in low-tax jurisdictions.
By
John Hintze
| May 15, 2018
Read More
People
J&J’s Dominic Caruso to Step Down as CFO
The company's longest-serving finance chief, who presided over three of its largest acquisitions, will be replaced by investor relations VP Joseph Wolk.
By
Matthew Heller
| March 21, 2018
Read More
Human Capital & Careers
J&J, Aetna CEOs Hit Fee-for-Service System
The chief executives of two health-care giants want the industry to move further toward payments based on quality of care.
By
David Katz
| November 14, 2017
Read More
Training
What Makes for a Public-Company CFO?
Five top finance chiefs tell how they got where they are, and what their potential successors need to do.
By
David McCann
| May 31, 2017
Read More
Financial Performance
J&J Posts $17.7B in Revenue, Misses Estimates
Tepid growth in pharmaceuticals and consumer products held back first-quarter sales but the company is still confident it will meet its full-year guidance.
By
Matthew Heller
| April 19, 2017
Read More
Strategy
J&J Boosts Drug Roster With $30B Actelion Deal
The largest acquisition in J&J's history gives it access to Actelion's portfolio of high-margin treatments for rare diseases.
By
Matthew Heller
| January 26, 2017
Read More
Strategy
J&J Sales Increase 1.7% But Miss Estimates
Earnings jumped 19% to $3.81 billion in the fourth quarter, but sales were hit by slowing demand for medical devices.
By
Matthew Heller
| January 24, 2017
Read More
Next
